Johanna Friedl-Naderer, Dyne Therapeutics’ chief commercial officer, sold 1,085 shares in two transactions priced from $18.88 to $24.35 per share. The sales leave her with 152,897 shares, giving investors the reported post-transaction ownership position and confirming both transactions used the S sale code.
Key Highlights
- The transactions occurred between Sep. 4 and Sep. 8, 2026.
- Both transactions carried SEC transaction code S, denoting sales.
- Johanna Friedl-Naderer owned 152,897 shares after the transactions.
Dyne Therapeutics, Inc. (NASDAQ: DYN) Chief Commercial Officer Johanna Friedl-Naderer sold 1,085 shares across two transactions priced between $18.88 and $24.35 per share. The transactions took place between Sep. 4 and Sep. 8, 2026. Friedl-Naderer held 152,897 Dyne shares after the sales.
8 Both entries used transaction code S, the SEC classification for a sale. Per-share prices ranged from $18.88 to $24.35. The transaction record identifies Friedl-Naderer as Dyne Therapeutics’ chief commercial officer.
FAQs
Q: How many Dyne Therapeutics shares did Johanna Friedl-Naderer sell?
A: Johanna Friedl-Naderer sold 1,085 Dyne Therapeutics shares across two transactions. The filing reports prices ranging from $18.88 to $24.35 per share.
Q: What was Johanna Friedl-Naderer’s remaining Dyne Therapeutics shareholding?
A: Following the two transactions, Johanna Friedl-Naderer held 152,897 shares of Dyne Therapeutics. This was her reported post-transaction ownership position after the sales conducted between Sep. 4 and Sep. 8, 2026.
Q: What does transaction code S mean for the Dyne Therapeutics stock sale?
A: Both transactions used SEC transaction code S, which denotes a sale in SEC transaction reporting. The filing applies that code to each of the two reported transactions.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.